Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares ...
The CEO of Germany's Merck KGaA on Thursday said a recovery in sales growth at its existing business means it can take a cautious approach to buying other companies, which are expensively priced.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback